Mark Zipkin is a freelance writer and consultant for the biotech and pharma industry, and a Central Operations Analyst for safety app Citizen. He was previously a staff writer at BioCentury, and has worked for SpringerNature journals including Nature Biotechnology and Nature Neuroscience. Mark lives in New Jersey with his wife and three children. Follow Mark on Twitter @MarkZipkin.

Articles by Mark Zipkin

Exscientia IPO Attracts Tech Investor Bets to AI Drug Discovery

Expert Advice 5 Oct 2021

How to Choose the Right Headquarters for Your Biotech Startup

Sanofi’s Translate Bio Buyout Shows Growing Hunger for mRNA Technology

Microbiome Medicines Could Power Up CAR-T Cell Therapies

Expert Advice 19 Jul 2021

How to Protect Your Intellectual Property as a Biotech Startup

Expert Advice 16 Jun 2021

What Makes a Biotech Executive Stand Out?

Startup Creator Launched to Fill Europe’s Microbiome Translational Gap

Expert Advice 17 May 2021

How to Spend Your Biotech Startup’s Money

BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors

Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens

Have European Investors Missed the Exosome ‘Gold Rush’?